NDC properties for NDC 9 0378-1941
NDC item 00378194101
| NDC 9 | 0378-1941 |
|---|---|
| NDC 10 | 0378-1941-01 |
| NDC Item | 00378194101 |
| packaging | 100 CAPSULE in 1 BOTTLE, PLASTIC (0378-1941-01) |
| ANDA | ANDA213912 |
| COLORTEXT | WHITE(white opaque) |
| Color | C48325 __ |
| FDA SPL set id | 745620 |
| Imprint code | MYLAN;LL;15 |
| Labeler | Mylan Pharmaceuticals Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 22 mm |
NDC item 00378194121
| NDC 9 | 0378-1941 |
|---|---|
| NDC 10 | 0378-1941-21 |
| NDC Item | 00378194121 |
| packaging | 21 CAPSULE in 1 BOTTLE, PLASTIC (0378-1941-21) |
| ANDA | ANDA213912 |
| COLORTEXT | WHITE(white opaque) |
| Color | C48325 __ |
| FDA SPL set id | 745620 |
| Imprint code | MYLAN;LL;15 |
| Labeler | Mylan Pharmaceuticals Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 22 mm |
NDC item 00480124421
| NDC 9 | 0480-1244 |
|---|---|
| NDC 10 | 0480-1244-21 |
| NDC Item | 00480124421 |
| packaging | 21 CAPSULE in 1 BOTTLE (0480-1244-21) |
| ANDA | ANDA201452 |
| COLORTEXT | white |
| Color | C48325 __ |
| FDA SPL set id | 644159 |
| Imprint code | NAT;15mg |
| Labeler | Teva Pharmaceuticals, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-03-03 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 18 mm |
NDC item 31722026001
| NDC 9 | 31722-260 |
|---|---|
| NDC 10 | 31722-260-01 |
| NDC Item | 31722026001 |
| packaging | 100 CAPSULE in 1 BOTTLE (31722-260-01) |
| ANDA | ANDA212414 |
| COLORTEXT | white,red |
| Color | C48325;C48326 __ |
| FDA SPL set id | 802288 |
| Imprint code | H;L5 |
| Labeler | Camber Pharmaceuticals, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-05-11 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 22 mm |
NDC item 31722026021
| NDC 9 | 31722-260 |
|---|---|
| NDC 10 | 31722-260-21 |
| NDC Item | 31722026021 |
| packaging | 21 CAPSULE in 1 BOTTLE (31722-260-21) |
| ANDA | ANDA212414 |
| COLORTEXT | white,red |
| Color | C48325;C48326 __ |
| FDA SPL set id | 802288 |
| Imprint code | H;L5 |
| Labeler | Camber Pharmaceuticals, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-05-11 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 22 mm |
NDC item 43598051301
| NDC 9 | 43598-513 |
|---|---|
| NDC 10 | 43598-513-01 |
| NDC Item | 43598051301 |
| packaging | 100 CAPSULE in 1 BOTTLE (43598-513-01) |
| ANDA | ANDA209348 |
| COLORTEXT | BLUE(blue opaque colored cap and body) |
| Color | C48333 __ |
| FDA SPL set id | 727151 |
| Imprint code | RDY;15;mg |
| Labeler | Dr. Reddy's Laboratories Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-07 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 19 mm |
NDC item 43598051321
| NDC 9 | 43598-513 |
|---|---|
| NDC 10 | 43598-513-21 |
| NDC Item | 43598051321 |
| packaging | 21 CAPSULE in 1 BOTTLE (43598-513-21) |
| ANDA | ANDA209348 |
| COLORTEXT | BLUE(blue opaque colored cap and body) |
| Color | C48333 __ |
| FDA SPL set id | 727151 |
| Imprint code | RDY;15;mg |
| Labeler | Dr. Reddy's Laboratories Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-07 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 19 mm |
NDC item 47781048601
| NDC 9 | 47781-486 |
|---|---|
| NDC 10 | 47781-486-01 |
| NDC Item | 47781048601 |
| packaging | 100 CAPSULE in 1 BOTTLE (47781-486-01) |
| ANDA | ANDA210480 |
| COLORTEXT | BROWN(caramel),GRAY |
| Color | C48332;C48324 __ |
| FDA SPL set id | 789803 |
| Imprint code | LP;640 |
| Labeler | Alvogen, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-03 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 18 mm |
NDC item 47781048677
| NDC 9 | 47781-486 |
|---|---|
| NDC 10 | 47781-486-77 |
| NDC Item | 47781048677 |
| packaging | 21 CAPSULE in 1 BOTTLE (47781-486-77) |
| ANDA | ANDA210480 |
| COLORTEXT | BROWN(caramel),GRAY |
| Color | C48332;C48324 __ |
| FDA SPL set id | 789803 |
| Imprint code | LP;640 |
| Labeler | Alvogen, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-03 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 18 mm |
NDC item 59651034501
| NDC 9 | 59651-345 |
|---|---|
| NDC 10 | 59651-345-01 |
| NDC Item | 59651034501 |
| packaging | 100 CAPSULE in 1 BOTTLE (59651-345-01) |
| ANDA | ANDA213885 |
| COLORTEXT | ORANGE(Dark Orange Opaque Cap, Dark Orange Opaque Body) |
| Color | C48331 __ |
| FDA SPL set id | 717399 |
| Imprint code | L;15 |
| Labeler | Aurobindo Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-03-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 59651034507
| NDC 9 | 59651-345 |
|---|---|
| NDC 10 | 59651-345-07 |
| NDC Item | 59651034507 |
| packaging | 1 BLISTER PACK in 1 CARTON (59651-345-07) / 7 CAPSULE in 1 BLISTER PACK |
| ANDA | ANDA213885 |
| COLORTEXT | ORANGE(Dark Orange Opaque Cap, Dark Orange Opaque Body) |
| Color | C48331 __ |
| FDA SPL set id | 717399 |
| Imprint code | L;15 |
| Labeler | Aurobindo Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-03-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 59651034521
| NDC 9 | 59651-345 |
|---|---|
| NDC 10 | 59651-345-21 |
| NDC Item | 59651034521 |
| packaging | 21 CAPSULE in 1 BOTTLE (59651-345-21) |
| ANDA | ANDA213885 |
| COLORTEXT | ORANGE(Dark Orange Opaque Cap, Dark Orange Opaque Body) |
| Color | C48331 __ |
| FDA SPL set id | 717399 |
| Imprint code | L;15 |
| Labeler | Aurobindo Pharma Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-03-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 60505453501
| NDC 9 | 60505-4535 |
|---|---|
| NDC 10 | 60505-4535-1 |
| NDC Item | 60505453501 |
| packaging | 100 CAPSULE in 1 BOTTLE (60505-4535-1) |
| ANDA | ANDA211022 |
| COLORTEXT | WHITE(White opaque),BLUE(Powder blue opaque) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 794910 |
| Imprint code | APO;L15 |
| Labeler | Apotex Corp. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 19 mm |
NDC item 60505453502
| NDC 9 | 60505-4535 |
|---|---|
| NDC 10 | 60505-4535-2 |
| NDC Item | 60505453502 |
| packaging | 21 CAPSULE in 1 BOTTLE (60505-4535-2) |
| ANDA | ANDA211022 |
| COLORTEXT | WHITE(White opaque),BLUE(Powder blue opaque) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 794910 |
| Imprint code | APO;L15 |
| Labeler | Apotex Corp. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 19 mm |
NDC item 63304004401
| NDC 9 | 63304-044 |
|---|---|
| NDC 10 | 63304-044-01 |
| NDC Item | 63304004401 |
| packaging | 100 CAPSULE in 1 BOTTLE (63304-044-01) |
| ANDA | ANDA211846 |
| COLORTEXT | white,WHITE |
| Color | C48325;C48325 __ |
| FDA SPL set id | 701728 |
| Imprint code | RL;;81 |
| Labeler | Sun Pharmaceutical Industries, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-03-04 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 63304004422
| NDC 9 | 63304-044 |
|---|---|
| NDC 10 | 63304-044-22 |
| NDC Item | 63304004422 |
| packaging | 21 CAPSULE in 1 BOTTLE (63304-044-22) |
| ANDA | ANDA211846 |
| COLORTEXT | white,WHITE |
| Color | C48325;C48325 __ |
| FDA SPL set id | 701728 |
| Imprint code | RL;;81 |
| Labeler | Sun Pharmaceutical Industries, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2023-03-04 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 69097038381
| NDC 9 | 69097-383 |
|---|---|
| NDC 10 | 69097-383-81 |
| NDC Item | 69097038381 |
| packaging | 21 CAPSULE in 1 BOTTLE, PLASTIC (69097-383-81) |
| ANDA | ANDA210435 |
| COLORTEXT | BLUE(pale blue and white) |
| Color | C48333 __ |
| FDA SPL set id | 698711 |
| Imprint code | Cipla15mg;383 |
| Labeler | Cipla USA Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |
NDC item 70710103301
| NDC 9 | 70710-1033 |
|---|---|
| NDC 10 | 70710-1033-1 |
| NDC Item | 70710103301 |
| packaging | 100 CAPSULE in 1 BOTTLE (70710-1033-1) |
| ANDA | ANDA210154 |
| COLORTEXT | WHITE(white opaque cap),BLUE(Light blue opaque body) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 770365 |
| Imprint code | 1033 |
| Labeler | Zydus Pharmaceuticals USA Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-12 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shapetext | capsule |
| Shape | C48336 |
| Size | 18 mm |
NDC item 70710103308
| NDC 9 | 70710-1033 |
|---|---|
| NDC 10 | 70710-1033-8 |
| NDC Item | 70710103308 |
| packaging | 21 CAPSULE in 1 BOTTLE (70710-1033-8) |
| ANDA | ANDA210154 |
| COLORTEXT | WHITE(white opaque cap),BLUE(Light blue opaque body) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 770365 |
| Imprint code | 1033 |
| Labeler | Zydus Pharmaceuticals USA Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-12 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shapetext | capsule |
| Shape | C48336 |
| Size | 18 mm |
NDC item 70771167901
| NDC 9 | 70771-1679 |
|---|---|
| NDC 10 | 70771-1679-1 |
| NDC Item | 70771167901 |
| packaging | 100 CAPSULE in 1 BOTTLE (70771-1679-1) |
| ANDA | ANDA210154 |
| COLORTEXT | WHITE(White opaque cap),BLUE(Light Blue opaque body) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 800438 |
| Imprint code | 1033 |
| Labeler | Zydus Lifesciences Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-12 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shapetext | capsule |
| Shape | C48336 |
| Size | 18 mm |
NDC item 70771167908
| NDC 9 | 70771-1679 |
|---|---|
| NDC 10 | 70771-1679-8 |
| NDC Item | 70771167908 |
| packaging | 21 CAPSULE in 1 BOTTLE (70771-1679-8) |
| ANDA | ANDA210154 |
| COLORTEXT | WHITE(White opaque cap),BLUE(Light Blue opaque body) |
| Color | C48325;C48333 __ |
| FDA SPL set id | 800438 |
| Imprint code | 1033 |
| Labeler | Zydus Lifesciences Limited |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-12 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shapetext | capsule |
| Shape | C48336 |
| Size | 18 mm |
NDC item 76282069947
| NDC 9 | 76282-699 |
|---|---|
| NDC 10 | 76282-699-47 |
| NDC Item | 76282069947 |
| packaging | 21 CAPSULE in 1 BOTTLE, PLASTIC (76282-699-47) |
| ANDA | ANDA210435 |
| COLORTEXT | BLUE(pale blue and white) |
| Color | C48333 __ |
| FDA SPL set id | 792852 |
| Imprint code | Cipla15mg;383 |
| Labeler | EXELAN PHARMACEUTICALS INC. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2022-09-06 |
| Marketing status | ACTIVE |
| Score | 1 |
| Shape | C48336 |
| Size | 21 mm |